Greenwich Biosciences Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Greenwich Biosciences's estimated annual revenue is currently $248M per year.
- Greenwich Biosciences's estimated revenue per employee is $201,000
- Greenwich Biosciences has 1234 Employees.
- Greenwich Biosciences grew their employee count by 55% last year.
- Greenwich Biosciences currently has 31 job openings.
What Is Greenwich Biosciences?
Greenwich Biosciences' vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. Epidiolex is Greenwich's lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. Greenwich's Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS). We have made a commitment to establish a fully integrated US operation to commercialize the product, with our US headquarters in Carlsbad, CA. Our Parent company (GW Pharmaceuticals, PLC), was founded in 1998 and is based in the UK. We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.keywords:N/A